MET and cancer: The reason for this is unclear but likely reflects differences in the pharmacological properties and target selectivity of AMG337 versus capmatinib, and the micro-environmental cues and signaling interactions present within the 3D tissue-like setting which may differentially influence the invasive capacity of cancer cells to c-Met inhibition.